Dr. Johnston has served on the Board of Directors since 2016 on the Science Committee and as Vice Chair of the Board since 2021.
Small molecule complexity is, and always will be, the foundation of therapeutic development, but synthesis uses this platform as a springboard to more potent and selective tools. In our portfolio of total synthesis, we have reported concise preparations of complex heterocyclic alkaloids serratezomine A and hapalindoles K, A, and G. Our recent work has moved beyond the practice of simply targeting the natural material to include molecularly edited versions (e.g. fluorinated derivatives). These strategic decisions and commitments to provide unique materials create unusual opportunities for collaboration.